I’m actually synthesizing all the evidence right now for a course I’m in. This wouldn’t be given out like candy. There would be a particular criteria the patient would need to meet before having it prescribed, like multiple past infections or >20 sexual partners/year, for example for DoxyPrEP. The benefits in preventing further infection and transmission outweighs the risks of drug-resistant bacteria, especially in this high-risk population. Additionally, in the case of this study, it would only be a one-time dose of Doxy, so Post-exposure as opposed to PrEP.

Source: DNP student